Business
Corxel will use the fundraising proceeds to advance the oral GLP-1 therapy CX11 through mid-stage development in the U.S., as well as prepare for its Phase III studies.
FEATURED STORIES
After winning a surprise approval for its hereditary angioedema drug Ekterly, KalVista is confident the oral offering will capture the lion’s share of the market for on-demand use.
Biohaven has suffered a few setbacks in recent months, including an FDA rejection and a missed $150 million benchmark payment, but CEO Vlad Coric looked for the brighter side at JPM, specifically emphasizing a serendipitous discovery that could get the company in the obesity game.
Henry Gosebruch, who has $3.5 billion in capital to deploy, is thinking broad as he steers the decades-old biotech out of years of turmoil.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
The deal’s termination was announced Thursday, months after bintrafusp alfa failed to hit the mark in a Phase II clinical trial as a potential second-line treatment for metastatic biliary tract cancer.
It was a busy week for clinical trial news. Here’s a look.
The companies said the collaboration recognizes a “great need for novel treatments in the area of neuropsychiatric medicine development.”
Biopharma companies and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers.
Jose Luis Casero Sanchez took advantage of his position in Goldman Sachs’ “control room” to gain insider knowledge of upcoming transactions, including those for several biopharma companies.
Expansion said much of the funds will go into its SMiRNA platform to find clinical candidates in myotonic DM1, FTD, ALS, and several other tauopathies.
Amicus Therapeutics is launching a next-generation genetic medicine company called Caritas Therapeutics, Inc. through a merger deal with ARYA Sciences Acquisition Corp IV.
Biomolecular condensates could hold the key to unlocking a number of neurological diseases that have baffled researchers the longest.
Celyad is focusing on advancing chimeric antigen receptor T cell (CAR T) therapies.
The Phase II trial, VLA150202, evaluated the safety and immunogenicity of VLA15 on 246 healthy adults aged 18 to 65 years old across the United States.